MiRs targeting CXCL12 were transferred via gap junctions from bone marrow stromal to breast cancer cells resulting in decreased CXCL12 levels and reduced proliferation thereby promoting cancer cell quiescence [114]. The gene discussed is CXCL12; the disease is cancer.